Cargando…

Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody

BACKGROUND: Patients with interstitial lung disease (ILD) are occasionally positive for anti-neutrophil cytoplasmic antibodies (ANCAs). Differences between ILDs secondary to microscopic polyangiitis (MPA) and isolated ANCA-positive idiopathic interstitial pneumonia (IIP) remain unclear. The aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xin, Peng, Min, Zhang, Ting, Li, Zongru, Song, Lan, Li, Mengtao, Shi, Juhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968287/
https://www.ncbi.nlm.nih.gov/pubmed/33726733
http://dx.doi.org/10.1186/s12890-021-01451-4
_version_ 1783666033548066816
author Sun, Xin
Peng, Min
Zhang, Ting
Li, Zongru
Song, Lan
Li, Mengtao
Shi, Juhong
author_facet Sun, Xin
Peng, Min
Zhang, Ting
Li, Zongru
Song, Lan
Li, Mengtao
Shi, Juhong
author_sort Sun, Xin
collection PubMed
description BACKGROUND: Patients with interstitial lung disease (ILD) are occasionally positive for anti-neutrophil cytoplasmic antibodies (ANCAs). Differences between ILDs secondary to microscopic polyangiitis (MPA) and isolated ANCA-positive idiopathic interstitial pneumonia (IIP) remain unclear. The aim of this study was to explore the differences in clinical features and outcomes between MPA-associated ILDs and isolated ANCA-positive IIPs. METHODS: We reviewed 1338 ILDs patients with available ANCA results and retrospectively analysed 80 patients who were ANCA-positive. MPA-associated ILDs (MPA-ILDs group) and isolated ANCA-positive IIPs (ANCA-IIPs group) were compared. RESULTS: Among 80 patients with ANCA-positive ILDs, 31 (38.75%) had MPA-ILDs, and 49 (61.25%) had isolated ANCA-positive IIPs. Compared with ANCA-IIPs group, patients in MPA-ILDs group had a higher proportion of fever (p = 0.006) and higher neutrophil count (p = 0.011), erythrocyte sedimentation rate (ESR) (p < 0.001) and C-reactive protein (CRP) (p = 0.005). Multivariable analysis showed that ESR level was an independent risk factor for mortality in all 80 ANCA-positive ILDs patients (HR 1.028, p = 0.001). Survival in MPA-ILDs group was lower than that in ANCA-IIPs group, and further stratified analysis revealed that ANCA-IIPs patients with elevated ESR or CRP had a worse prognosis than those with normal inflammation markers, with 5-year cumulative survival rates of 60.00%, 86.90% and 100.00% in MPA-ILDs and ANCA-IIPs with and without elevated inflammation markers, respectively. CONCLUSIONS: Among patients with ANCA-positive ILDs, the prognoses of ANCA-IIPs with normal inflammation markers, ANCA-IIPs with elevated inflammation markers and MPA-ILDs were sequentially poorer. Therefore, stratified treatment should be considered in the management of ILDs patients positive for ANCAs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01451-4.
format Online
Article
Text
id pubmed-7968287
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79682872021-03-19 Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody Sun, Xin Peng, Min Zhang, Ting Li, Zongru Song, Lan Li, Mengtao Shi, Juhong BMC Pulm Med Research Article BACKGROUND: Patients with interstitial lung disease (ILD) are occasionally positive for anti-neutrophil cytoplasmic antibodies (ANCAs). Differences between ILDs secondary to microscopic polyangiitis (MPA) and isolated ANCA-positive idiopathic interstitial pneumonia (IIP) remain unclear. The aim of this study was to explore the differences in clinical features and outcomes between MPA-associated ILDs and isolated ANCA-positive IIPs. METHODS: We reviewed 1338 ILDs patients with available ANCA results and retrospectively analysed 80 patients who were ANCA-positive. MPA-associated ILDs (MPA-ILDs group) and isolated ANCA-positive IIPs (ANCA-IIPs group) were compared. RESULTS: Among 80 patients with ANCA-positive ILDs, 31 (38.75%) had MPA-ILDs, and 49 (61.25%) had isolated ANCA-positive IIPs. Compared with ANCA-IIPs group, patients in MPA-ILDs group had a higher proportion of fever (p = 0.006) and higher neutrophil count (p = 0.011), erythrocyte sedimentation rate (ESR) (p < 0.001) and C-reactive protein (CRP) (p = 0.005). Multivariable analysis showed that ESR level was an independent risk factor for mortality in all 80 ANCA-positive ILDs patients (HR 1.028, p = 0.001). Survival in MPA-ILDs group was lower than that in ANCA-IIPs group, and further stratified analysis revealed that ANCA-IIPs patients with elevated ESR or CRP had a worse prognosis than those with normal inflammation markers, with 5-year cumulative survival rates of 60.00%, 86.90% and 100.00% in MPA-ILDs and ANCA-IIPs with and without elevated inflammation markers, respectively. CONCLUSIONS: Among patients with ANCA-positive ILDs, the prognoses of ANCA-IIPs with normal inflammation markers, ANCA-IIPs with elevated inflammation markers and MPA-ILDs were sequentially poorer. Therefore, stratified treatment should be considered in the management of ILDs patients positive for ANCAs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01451-4. BioMed Central 2021-03-16 /pmc/articles/PMC7968287/ /pubmed/33726733 http://dx.doi.org/10.1186/s12890-021-01451-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Sun, Xin
Peng, Min
Zhang, Ting
Li, Zongru
Song, Lan
Li, Mengtao
Shi, Juhong
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
title Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
title_full Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
title_fullStr Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
title_full_unstemmed Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
title_short Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
title_sort clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968287/
https://www.ncbi.nlm.nih.gov/pubmed/33726733
http://dx.doi.org/10.1186/s12890-021-01451-4
work_keys_str_mv AT sunxin clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody
AT pengmin clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody
AT zhangting clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody
AT lizongru clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody
AT songlan clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody
AT limengtao clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody
AT shijuhong clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody